In a pharmaceutical transaction, due diligence typically focuses on revenue, contracts, intellectual property, customers, employees, facilities, inventory, and financial liabilities.
But there is another area that can quietly create significant risk after closing: state licensing and regulatory compliance.
A company may appear to have a clean licensing portfolio, only for an acquisition to reveal expired licenses, missing registrations, incorrect business information, unaddressed change-of-ownership requirements, or licenses that no longer align with the company’s actual operations.
For companies operating across multiple states, these issues can become even more complicated. Each state can have its own licensing requirements, application processes, notification obligations, and rules surrounding a change of ownership or control.
That means licensing due diligence should not be treated as an administrative task that happens after the transaction. It should be part of the acquisition strategy from the beginning.
Why Licensing Matters in an Acquisition
A license is more than a document or a record in a state regulatory database. It represents a company’s authorization to conduct certain activities in a particular jurisdiction.
When a company is acquired, the ownership, management, corporate structure, facilities, business activities, products, or distribution model may change. Any of these changes can affect state licensing requirements.
Consider a pharmaceutical distributor acquiring another distributor. The target company may operate in states where the acquiring company does not currently hold the appropriate wholesale distributor licenses. The target may also have facilities, business activities, or distribution relationships that create additional regulatory obligations for the combined organization.
A pharmaceutical manufacturer may encounter similar issues when acquiring a company with additional facilities, product lines, contract manufacturing relationships, or distribution activities.
Compounding pharmacy acquisitions can present another layer of complexity, particularly when the target operates as a 503A pharmacy or 503B outsourcing facility and conducts business across multiple states.
The important question is not simply, “Does the company have the licenses it needs today?” It is: “Will the combined organization have the licenses and registrations it needs to legally operate after the transaction?”
That is a very different question.
The Licensing Due Diligence Gap
Traditional M&A due diligence often examines whether a target company possesses required licenses and whether those licenses are current. That is important but it is only the starting point.
A more complete licensing due diligence process should evaluate whether the target’s licensing portfolio accurately reflects its actual business operations.
A company may hold licenses in 35 states and appear to have a well-managed portfolio. But what if it recently expanded into several new markets? What if it added a new distribution facility, began selling additional products, changed its corporate structure, started using a new third-party logistics provider, or changed the nature of its business activities?
The license portfolio may no longer tell the complete story.
This is one of the most important licensing risks hiding inside an acquisition. The licenses may exist but they may not fully align with the business.
That distinction matters because state regulators generally evaluate a company’s authorization based on the activities it actually performs, not simply the licenses it happens to have on file.
Change of Ownership Is Not Always a Simple Change
One of the most important licensing considerations in an acquisition is the change of ownership, commonly referred to as a CHOW.
A common misconception is that once the purchase agreement is signed and the transaction closes, the acquiring company can simply update the existing licenses. State requirements can be much more complicated.
Depending on the jurisdiction and type of license involved, a change of ownership or control may require advance notification, a new application, an amendment, supporting corporate documentation, updated ownership information, new corporate officer information, or other regulatory filings.
In some circumstances, a state may allow an existing license to remain in place subject to certain requirements. In others, a new license application may be necessary.
The timing can also matter. Some state agencies may require action before closing, while others may have post-closing notification requirements.
There is no universal CHOW process that applies across every state and every regulated business. That is why change of ownership licensing requirements should be evaluated on a state-by-state basis before the transaction closes.
Pharmaceutical Manufacturers Face Their Own Licensing Risks
For pharmaceutical manufacturers, an acquisition can introduce licensing considerations that extend well beyond the corporate entity itself.
A transaction may involve manufacturing facilities, contract manufacturing organizations, product registrations, distribution activities, nonresident licensing, additional corporate entities, and new products or business activities. The acquiring company may also inherit a business model that differs from its own.
For example, a manufacturer that primarily produces products through its own facilities may acquire a company that relies extensively on contract manufacturing or third-party logistics providers. That change in operating structure can affect how the combined organization needs to approach pharmaceutical licensing and state regulatory compliance.
The licensing analysis therefore needs to look beyond the question of whether the target is licensed. It should consider whether the post-acquisition business model will be appropriately licensed in every applicable jurisdiction.
That is especially important when the acquisition expands a company’s geographic footprint. Entering a new state can create new licensing obligations, and those requirements can differ depending on the products being handled, the activities being performed, and the type of facility or entity involved.
Wholesale Distributors and 3PLs Should Look Beyond Their Existing Footprint
For pharmaceutical distributors and third-party logistics providers, geographic expansion can create significant licensing exposure.
An acquiring company may have a well-managed licensing portfolio in the states where it currently operates. But acquiring another distributor can immediately expand the company’s operational footprint. The target may hold licenses in states where the acquiring company does not. It may also operate facilities or conduct business activities that require different licenses or registrations.
This makes wholesale distributor licensing and 3PL licensing an important part of M&A due diligence.
It is also important to evaluate licenses against actual operations. A licensing portfolio should not simply be viewed as a list of states. The analysis should consider where products are being distributed, what activities are taking place, which entities are performing those activities, and how the combined organization will operate after the transaction.
A company can therefore face licensing risk even when every license in the target’s portfolio appears current.
Compounding Pharmacies Have Additional Licensing Complexity
Compounding pharmacy acquisitions deserve particular attention because of the regulatory distinctions surrounding different types of compounding operations.
A transaction involving a 503A compounding pharmacy or 503B outsourcing facility may require a detailed review of state pharmacy licensing, nonresident pharmacy requirements, facility information, and other applicable state-specific obligations.
The distinction between 503A and 503B operations is important because the regulatory framework and business model can differ significantly.
An acquiring company should understand exactly what the target does, where it ships products, how its facilities are structured, and what licenses and registrations support those activities.
For a 503A pharmacy, the licensing analysis may involve pharmacy licenses and nonresident pharmacy licenses across multiple states. A 503B outsourcing facility may involve a different combination of state and federal considerations, facility-specific requirements, and state interpretations of applicable standards.
The key is that compounding pharmacy licensing should be evaluated based on the actual business model, rather than simply the license type listed in a regulatory database.
The License May Be Current, But the Information May Not Be
Another commonly overlooked issue during licensing due diligence is whether the information associated with a license remains accurate. A license can be active while the information associated with it is outdated.
An acquisition may reveal changes involving the legal entity, corporate ownership, business address, facility address, corporate officers, designated representatives, or other information that may need to be reported to a state regulatory agency.
This creates an important distinction between having an active license and having an accurate and compliant license portfolio.
That distinction can be particularly important during an acquisition because ownership and corporate information are likely to change as part of the transaction.
A licensing review should therefore look at the information associated with each license, not simply whether the license shows an active status.
What Happens When Licensing Issues Are Discovered After Closing?
This is where a licensing problem can become a business problem.
If licensing gaps are discovered after an acquisition closes, the new owner may have to address them while simultaneously integrating employees, systems, facilities, customers, products, and operations.
What looked like a relatively straightforward acquisition can suddenly involve unexpected applications, state notifications, regulatory correspondence, fees, inspections, and additional compliance work.
In some cases, these requirements may delay the integration of the acquired business. In others, they may require changes to how certain operations are conducted while licensing matters are resolved.
There is also the potential for regulatory exposure if a company discovers that it has been operating without a required license or failed to satisfy a state notification requirement.
The earlier these issues are identified, the more opportunity there is to plan for them.
Licensing Due Diligence Should Start Before the Deal Closes
The best time to identify licensing risk is before the acquisition is complete.
That does not mean licensing should become an obstacle to every transaction. Instead, it should become a component of the broader transaction-planning process.
A thorough licensing review should establish what licenses the target holds, whether they are active and in good standing, whether the licenses accurately reflect the company’s current operations, and what happens to each license as ownership changes.
The review should also identify the actions that may be required before and after closing.
This is particularly important when a transaction involves multiple states. A pharmaceutical company operating in 40 states may face 40 different regulatory considerations when its ownership or operating structure changes.
Understanding those requirements in advance allows legal, compliance, operations, and transaction teams to build licensing activities into the overall M&A timeline rather than discovering them after the deal is complete.
Don’t Let Licensing Become the Hidden Cost of Growth
Acquisitions are designed to accelerate growth. They can expand geographic reach, increase production capacity, add new products, introduce new customers, and create operational efficiencies.
But growth also creates regulatory complexity. Every new facility, state, product, business activity, ownership structure, or distribution relationship can potentially change a company’s licensing requirements.
That is why multi-state licensing management should be considered part of the broader integration strategy.
Companies should not wait until after a transaction to ask whether the new organization is properly licensed. The better approach is to understand the licensing implications while there is still time to plan, budget, and execute the necessary actions.
From Licensing Due Diligence to Deal Readiness
Strong licensing due diligence does more than reduce compliance risk. It can give an acquiring company a clearer picture of what it is actually purchasing.
Understanding the target’s licensing portfolio before closing can help identify potential gaps, anticipate CHOW requirements, estimate application costs and timelines, determine which states require additional action, and reduce the possibility of licensing-related delays during integration.
It can also help companies become more deal-ready before entering the acquisition process.
For organizations that regularly pursue acquisitions, licensing should not be evaluated only when a transaction is underway. Maintaining an accurate, current understanding of the company’s licensing footprint can make future transactions easier to evaluate and execute.
The Bottom Line
An acquisition can change much more than the name on a corporate document.
It can change who owns a business, how it operates, where it operates, what products it handles, which facilities it uses, and how those products are distributed. Each of those changes can have licensing implications.
For pharmaceutical manufacturers, wholesale distributors, 3PLs, 503A pharmacies, and 503B outsourcing facilities, state licensing due diligence should be part of the M&A process, not an afterthought once the deal is complete.
The most successful transactions are not simply the ones that close. They are the ones where the acquiring company understands what it is buying, what regulatory obligations come with it, and what needs to happen next.
Before your next acquisition closes, make sure you know what is hiding in the license portfolio.
How State License Servicing Can Help
State License Servicing helps pharmaceutical manufacturers, distributors, pharmacies, and other regulated businesses navigate the complexities of multi-state licensing and regulatory compliance.
Our team can evaluate an organization’s licensing footprint, identify potential gaps and requirements, and help companies understand the licensing actions associated with business changes, including acquisitions and changes of ownership (CHOWs).
With licensing specialists and in-house legal and compliance expertise, SLS provides the human oversight needed to evaluate complex state requirements across the United States.
Whether you are preparing for an acquisition, integrating a newly acquired company, or simply want to understand the licensing risks within your current portfolio, State License Servicing can help turn licensing complexity into a clearer path forward.
Planning an acquisition? Contact State License Servicing to discuss your licensing due diligence and transaction-readiness needs.